GENT: Q2 2024 saw robust sales, margin gains, and pipeline milestones for Gentian Diagnostics

About this update from Gentian Diagnostics Asa

Gentian Diagnostics delivered double-digit revenue and profit growth in Q2 2024, driven by strong fCALⓇ turbo and Cystatin C sales, improved gross margin, and pipeline progress. New executive hires and positive clinical data support long-term growth ambitions.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa